CSTE Position Statement(s)
Clinical DescriptionStaphylococcus aureus can produce a variety of syndromes with clinical manifestations including skin and soft tissue lesions, empyema, pyarthrosis, bloodstream infection, pneumonia, osteomyelitis, septic arthritis, endocarditis, sepsis, and meningitis.
Laboratory Criteria For Diagnosis
- Isolation of S. aureus from any body site. AND
- Intermediate or high-level resistance of the S. aureus isolate to vancomycin, detected and defined according to NCCLS* approved standards and recommendations (MIC: 8-16 µg/ml for VISA and MIC:≥32 µg/ml for VRSA).
ConfirmedA clinically compatible case of vancomycin-intermediate or vancomycin-resistant S. aureus that is laboratory-confirmed (MIC: 8-16 µg/ml for VISA and MIC: ≥32 µg/ml for VRSA).
Data to be collected: A standardized data collection form should be used for all reported vancomycin-intermediate or vancomycin-resistant S. aureus through the National Notifiable Diseases Surveillance System.
* National Committee for Clinical Laboratory Standards
- NCCLS. (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard 6th ed., vol. 23, No. 2. Approved standard M7-A5. NCCLS, Wayne, Pa.
- NCCLS. (2003) Performance standards for antimicrobial susceptibility testing; Thirteenth informational supplement M100-S13 (M7). NCCLS, Wayne, Pa.
- Clinical and Laboratory Standards Institute/NCCLS. Performance Standards for Antimicrobial Susceptibility Testing. Sixteenth informational supplement. M100-S16. Wayne, PA: CLSI, 2006.